August 22, 2025

Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma

In long-term results from the CARTITUDE-1 trial, investigators had found that the autologous cellular immunotherapy ciltacabtagene autoleucel was potentially curative for one-third of patients with he...

The ASCO Post

August 22, 2025

John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director

An internationally lauded researcher and clinical specialist in hematologic malignancies has been appointed Director of UPMC Hillman Cancer Center, effective November 2025.

The ASCO Post

August 22, 2025

Dendrimer-Based SN38 Nanoparticle Shows Favorable Safety and Activity in Advanced Solid Tumors

In an early-phase study reported in the Journal of Clinical Oncology, Liu et al evaluated the efficacy and safety of DEP-SN38, a polylysine-based dendrimer-nanoparticle conjugate of SN38, the active m...

The ASCO Post

August 22, 2025

Patient Awareness of Pharmacogenomic Testing Remains Low, ACS CAN Survey Reports

Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer...

The ASCO Post

August 22, 2025

PSMA PET/CT and Salvage Radiotherapy in Recurrent Prostate Cancer

Use of prostate-specific membrane antigen (PSMA) PET/CT before undergoing salvage radiotherapy was associated with an improved overall survival and biochemical recurrence–free survival compared those ...

The ASCO Post

August 22, 2025

Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy

In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estro...

The ASCO Post

August 22, 2025

Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?

In a substudy of the Australian phase II ENZA-p trial, baseline PSMA-PET total tumor volume was prognostic for overall survival and predictive for a beneficial effect on overall survival in patients r...

The ASCO Post

August 22, 2025

Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods

In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre...

The ASCO Post

August 22, 2025

Age Threshold for Survival Benefit of Adding Oxaliplatin to Adjuvant Chemotherapy in Stage II and III Colorectal Cancer

In a Korean retrospective study reported in JAMA Network Open, Bong et al found that the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy was associated with a survival benefit ...

The ASCO Post